Skip to content
Screener

Opko Health OPK Financing Cash Flow

Financing Cash Flow at other companies

Quest Diagnostics logo
Quest DiagnosticsDGX
-$229M+21.8%
Regenxbio logo
RegenxbioRGNX
$17.57M-87.4%
Rigel Pharmaceuticals logo
Rigel PharmaceuticalsRIGL
-$10.92M-2,356%
Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
$394.19M+13,285%
PTH
Pelthos TherapeuticsPTHS
$27.52M+10,909%
Exelixis logo
ExelixisEXEL
-$343.88M-8.7%

Other financials

Income statement

See full
Revenue$163.6M+4.3%
Gross profit$80.0M+62.0%
Operating income-$7.0M+88.4%
Net income-$8.4M+94.3%
EPS (diluted)-$0.01+94.7%

Balance sheet

See full
Cash & equivalents$40.6M-62.5%
Total debt$49.9M-7.5%
Total equity$1.2B-8.7%
Total assets$1.8B-7.3%

Cash flow

See full
Operating cash flow-$43.5M+47.9%
CapEx$3.0M-8.5%
Free cash flow-$46.5M+46.4%

Valuation

See full
Market cap$985.15M-2.3%
P/S1.7×+0.2×

Profitability

See full
Gross margin40.8%+8.1pp
Operating margin-8.2%-3.5pp
Net margin-12.4%-4.3pp
FCF margin-22.8%-6.7pp

Returns & leverage

See full
Return on equity-5.9%-2.1pp
Debt / equity0.0×
Current ratio3.3×-0.1×

Where this comes from

Reported directly by Opko Health in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.

The source filing: Opko Health’s 10-Q, filed July 27, 2026.

Filed
Jul 27, 2026, 4:12 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-318090
Line itemFor the six months ended June 30, 2026For the six months ended June 30, 2025
Borrowings on lines of credit18,66416,636
Repayments of lines of credit(18,721)(19,387)
Settlement of convertible notes(62,382)
Net cash used in financing activities(18,183)(83,511)
Effect of exchange rate changes on cash, cash equivalents and restricted cash(1,053)3,571
Net (decrease) increase in cash, cash equivalents and restricted cash(68,310)(160,220)
Cash, cash equivalents and restricted cash at beginning of period382,742445,615
Cash, cash equivalents and restricted cash at end of period$314,432$285,395

Item 1. Financial Statements

FAQ

What is Opko Health's financing cash flow?
Opko Health (OPK) reported financing cash flow of -$13.03M in Q2 2026.
How has Opko Health's financing cash flow changed year-over-year?
Opko Health's financing cash flow increased by 83.6% year-over-year, from -$79.49M to -$13.03M.
What does financing cash flow mean?
Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.

Ask your AI about Opko Health's financing cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude